SCHEMBL4607688

SCHEMBL4607688

CC(=O)c1ccc2c(c1)CC(NC(=O)C(F)(F)F)C2

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
CA1 P00915 7/20 0.45
CA2 P00918 7/20 0.45
CA12 O43570 6/20 0.45
CA7 P43166 6/20 0.45
CA14 Q9ULX7 6/20 0.45
CA9 Q16790 4/20 0.44
APOB P04114 5/20 0.42
MTTP P55157 4/20 0.42
PGR P06401 1/20 0.41
HSD17B1 P14061 1/20 0.40
POLB P06746 1/20 0.39
APEX1 P27695 1/20 0.39
RECQL P46063 1/20 0.39
HPGD P15428 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
MCHR1 Q99705 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10405252 0.83 CA1 (0.61) MAPTNPC1RAB9ACA1CA2
SCHEMBL5737230 0.82 CA1 (0.42) MAPTRAB9ACA1CA2CA12
SCHEMBL3441786 0.79 CA1 (0.43) CA1CA2CA12CA7CA14
SCHEMBL2075952 0.79 NPC1 (0.52) MAPTNPC1RAB9ACA1CA2
SCHEMBL4607263 0.79 CA1 (0.43) CA1CA2CA12CA7CA14
SCHEMBL2283276 0.78 MAPT (0.50) MAPTNPC1RAB9A
SCHEMBL4124063 0.76 CA1 (0.39) CA1CA2CA12CA7CA14
SCHEMBL7690123 0.76 CA1 (0.43) RAB9ACA1CA2CA12CA7
SCHEMBL7248144 0.76 CA1 (0.43) RAB9ACA1CA2CA12CA7
SCHEMBL4607791 0.75 APOB (0.36) CA1CA2CA12CA7CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1487781-B1 PROCESS FOR PREPARING 2-AMINOINDAN DERIVATIVES NOVARTIS AG (CH) 2008-07-23 EP claimed
CN-1268605-C Process for preparing 2-aminoindan derivatives NOVARTIS AG (CH) 2006-08-09 CN claimed
US-6933410-B2 Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine NOVARTIS AG (CH) 2005-08-23 US claimed
CN-1639111-A Process for preparing 2-aminoindan derivatives NOVARTIS AG (CH) 2005-07-13 CN claimed
US-20030187301-A1 Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine NOVARTIS AG (CH) 2003-10-02 US claimed
EP-1487781-B1 PROCESS FOR PREPARING 2-AMINOINDAN DERIVATIVES NOVARTIS AG (CH) 2008-07-23 EP disclosed
EP-1487781-B1 PROCESS FOR PREPARING 2-AMINOINDAN DERIVATIVES NOVARTIS AG (CH) 2008-07-23 EP disclosed
CN-1268605-C Process for preparing 2-aminoindan derivatives NOVARTIS AG (CH) 2006-08-09 CN disclosed
US-6933410-B2 Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine NOVARTIS AG (CH) 2005-08-23 US disclosed
CN-1639111-A Process for preparing 2-aminoindan derivatives NOVARTIS AG (CH) 2005-07-13 CN disclosed
US-20030187301-A1 Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine NOVARTIS AG (CH) 2003-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187301-A1 Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine NAT1, AADAC, IDH3A MAPT 2277/4885NPC1 2911/4885RAB9A 3654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.